Biotech Startups

Structure-based small-molecule drug design targeting protein aggregation diseases.

1 investor

Adthera is a biotech company offering capabilities in process development, manufacturing science and technology, and quality and regulatory compliance. It operates from locations in Birmingham and London, United Kingdom.

1 investor

Aduro Biotech was a Berkeley, CA clinical-stage biopharmaceutical company developing cancer immunotherapies, including STING-pathway agonists and Listeria-based vaccine platforms derived from UC Berkeley research.

1 investor

Advanced BioDesign is a clinical-stage French biotechnology company developing small-molecule ALDH1 enzyme inhibitors to overcome drug resistance in chemotherapy-resistant cancers. Its work targets oncology indications such as acute myeloid leukemia, non-small cell lung cancer, and melanoma, alongside a companion diagnostic to stratify patients.

1 investor

Advanced NanoTherapies (ANT) develops next-generation drug-coated balloons (DCBs) using nanotechnology to treat vascular disease. The company operates in the medical device and nanomedicine field, focused on cardiovascular and endovascular interventions.

1 investor

Advanced Silicon Group works in nanotechnology, using the tagline "Nanotechnology for Life."

1 investor

AdvancedAg develops live microbial biological systems and fermentation-based technologies for agriculture and water/environmental applications, serving growers, dealers, and industry partners across North America. The company focuses on microbial consortiums and agronomic strategies aimed at improving crop performance, soil health, and reducing input dependence.

1 investor

Advanced Enzymes is a company in the enzyme/biotech industry; the page shown is an investor relations section with quarterly financial results, shareholding patterns, and corporate governance reports.

1 investor

ADvantage Therapeutics is a biopharmaceutical company engaged in therapeutic drug development and clinical research, including NIH/PHS-funded studies evaluating the safety and effectiveness of drugs and treatments.

1 investor

Advantageous Systems combines nanotechnology, material science, and biotechnology to develop smart materials for medical devices, therapeutics, and clean technology applications. The company has commercialized nanotechnology solutions, particularly in water treatment.

1 investor

ADVANZ PHARMA Corp. Limited is a pharmaceutical company with a research and development pipeline of products. The page shown is a legal disclaimer gateway relating to a formal sale process under the UK City Code on Takeovers and Mergers.

1 investor

Adventris is a biotechnology company developing cancer immunotherapy treatments.

1 investor

Advesya is a clinical-stage biotech company developing cancer and autoimmune disease therapies that target IL-1RAP, an antigen upregulated in various cancers and autoimmune conditions. A spin-out from the French Blood Institute (EFS), it is developing a CAR T-cell therapy (CCTx-001) and an antibody-drug conjugate (ADV-101).

1 investor

The site presents ADYNOVATE, a PEGylated recombinant antihemophilic Factor VIII injectable used to treat and control bleeding in adults and children with hemophilia A. It provides prescribing and safety information for patients and healthcare providers.

1 investor

Aenova is a global contract development and manufacturing organization (CDMO) serving pharmaceutical, biopharmaceutical, and healthcare companies. With 14 manufacturing sites across Europe and the U.S., the company provides end-to-end services including drug formulation, sterile and non-sterile manufacturing, packaging, and regulatory support.

1 investor

AEON Biopharma develops botulinum toxin biosimilars and therapeutic neurotoxin treatments for patients with neuromuscular disorders. The company focuses on expanding access to high-quality neurotoxin therapies through proprietary drug development.

1 investor

Aequor develops EPA-approved green chemical compounds that replace toxic biocides for controlling bacteria, fungi, and marine fouling in industrial and consumer applications. The company offers customized product formulations and consulting services to help clients reduce chemical toxicity while cutting costs and carbon emissions.

1 investor

Aerion Bioscience develops a 6-protein biomarker panel for early detection and staging of lung cancer. The company is conducting clinical testing to validate the panel's ability to detect lung cancer, distinguish its stages and aggressiveness, and identify other lung conditions.

1 investor

AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers. Its pipeline targets high-risk respiratory patients, including older individuals and those with dexterity limitations who benefit from nebulized delivery.

1 investor

AesculaTech designs custom smart materials with adaptive responses to stimuli for biomedical, commercial, and industrial applications. Its materials can be tailored for biocompatibility and strength, with an initial focus on ophthalmic treatment of dry eye disease.

1 investor

Aevum develops therapeutic molecules derived from exercise to treat disease. The company operates in the drug discovery and biotech field.

1 investor

1 investor

Affibody is a biotechnology company developing radiopharmaceuticals and radioligand therapeutics based on its proprietary Affibody platform, aimed at treating cancer patients. Its pipeline also includes partnership programs in immunology.

1 investor

Afimmune develops new medicines for rare and inflammatory diseases through drug discovery and development programs at various clinical and pre-clinical stages.

1 investor